Filippo Pietrantonio

List of Publications by Citations

194 papers	4,693 citations	36 h-index	59 g-index
209 ext. papers	6,372 ext. citations	6.2 avg, IF	5.25 L-index

#	Paper	IF	Citations
194	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. *European Journal of Cancer*, **2015**, 51, 587-94	7.5	329
193	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. *Nature*, **2017**, 552, 116-120	50.4	290
192	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. *JAMA Oncology*, **2019**, 5, 343-350	13.4	134
191	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	126
190	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. *Journal of Clinical Oncology*, **2019**, 37, 3392-3400	2.2	123
189	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. *Nature Communications*, **2016**, 7, 13665	17.4	121
188	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 2414-2422	12.9	111
187	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. *Annals of Oncology*, **2015**, 26, 2092-7	10.3	110
186	Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. *Cancer Discovery*, **2016**, 6, 1315-1333	24.4	107
185	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. *Cell Metabolism*, **2018**, 28, 848-865.e6	24.6	107
184	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncology, The*, **2020**, 21, 497-507	21.7	98
183	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. *Annals of Oncology*, **2015**, 26, 1994-1999	10.3	93
182	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. *Oncologist*, **2016**, 21, 988-94	5.7	72
181	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. *Cancer Discovery*, **2016**, 6, 963-71	24.4	71
180	Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. *Critical Reviews in Oncology/Hematology*, **2016**, 100, 209-22	7	68
179	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. *European Urology*, **2020**, 78, 195-206	10.2	67
178	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. *Clinical Cancer Research*, **2018**, 24, 1082-1089	12.9	58

177	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *International Journal of Cancer*, **2016**, 139, 2859-2864	7.5	57
176	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. *Nature Medicine*, **2020**, 26, 919-931	50.5	55
175	Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. *Journal of Gastrointestinal Oncology*, **2017**, 8, 148-163	2.8	54
174	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. *Annals of Oncology*, **2014**, 25, 404-8	10.3	51
173	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. *Critical Reviews in Oncology/Hematology*, **2015**, 96, 156-66	7	50
172	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. *Annals of Oncology*, **2017**, 28, 3009-3014	10.3	48
171	A review on biomarkers for prediction of treatment outcome in gastric cancer. *Anticancer Research*, **2013**, 33, 1257-66	2.3	48
170	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. *Annals of Oncology*, **2018**, 29, 1394-1401	10.3	47
169	Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. *PLoS ONE*, **2014**, 9, e108940	3.7	46
168	Toward the molecular dissection of peritoneal pseudomyxoma. *Annals of Oncology*, **2016**, 27, 2097-2103	10.3	45
167	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. *British Journal of Clinical Pharmacology*, **2015**, 80, 581-8	3.8	41
166	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. *European Journal of Cancer*, **2015**, 51, 800-7	7.5	40
165	Gastric cancer: Translating novels concepts into clinical practice. *Cancer Treatment Reviews*, **2019**, 79, 101889	14.4	39
164	Role of cMET in the development and progression of colorectal cancer. *International Journal of Molecular Sciences*, **2013**, 14, 18056-77	6.3	38
163	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncology*, **2019**, 5, 1268-1275	13.4	37
162	FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. *Oncologist*, **2014**, 19, 845-50	5.7	37
161	Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. *Clinical Cancer Research*, **2019**, 25, 3954-3961	12.9	36
160	Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. *Annals of Surgical Oncology*, **2018**, 25, 878-884	3.1	36

159	MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises. *Current Pharmaceutical Design*, **2014**, 20, 3982-90	3.3	36
158	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. *Journal of Clinical Oncology*, **2019**, 37, 3099-3110	2.2	35
157	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. *European Journal of Cancer*, **2017**, 73, 74-84	7.5	32
156	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. *Annals of Oncology*, **2017**, 28, 555-561	10.3	32
155	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. *British Journal of Clinical Pharmacology*, **2014**, 78, 1228-37	3.8	32
154	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. *Oncologist*, **2018**, 23, 1178-1187	5.7	31
153	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. *Oncologist*, **2015**, 20, 1261-5	5.7	29
152	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the BRAF BeCoolR study. *European Journal of Cancer*, **2019**, 118, 121-130	7.5	29
151	Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?. *Oncology*, **2013**, 84, 191-9	3.6	27
150	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. *Cancer Research*, **2019**, 79, 5884-5896	10.1	26
149	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. *Scientific Reports*, **2019**, 9, 2858	4.9	26
148	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. *Journal of Translational Medicine*, **2016**, 14, 125	8.5	26
147	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. *Annals of Surgical Oncology*, **2017**, 24, 167-175	3.1	26
146	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. *BMC Cancer*, **2020**, 20, 683	4.8	26
145	Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. *Gastric Cancer*, **2016**, 19, 412-420	7.6	25
144	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. *International Journal of Cancer*, **2015**, 137, 1467-74	7.5	25
143	Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. *ESMO Open*, **2021**, 6, 100036	6	25
142	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. *Gastric Cancer*, **2017**, 20, 825-833	7.6	24

141	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. *Radiotherapy and Oncology*, **2015**, 117, 315-21	5.3	24
140	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. *Oncotarget*, **2017**, 8, 16887-16898	3.3	24
139	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. *Clinical Colorectal Cancer*, **2019**, 18, 125-132.e2	3.8	23
138	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. *Targeted Oncology*, **2018**, 13, 227-234	5	23
137	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. *Targeted Oncology*, **2014**, 9, 155-62	5	23
136	Identification and characterization of a novel rearrangement in a colorectal cancer patient. *Oncotarget*, **2017**, 8, 55353-55360	3.3	23
135	Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. *World Journal of Gastroenterology*, **2014**, 20, 4516-25	5.6	23
134	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. *European Journal of Cancer*, **2017**, 71, 43-50	7.5	22
133	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. *British Journal of Cancer*, **2020**, 123, 403-409	8.7	22
132	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. *Annals of Oncology*, **2018**, 29, 1800-1806	10.3	22
131	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. *British Journal of Cancer*, **2017**, 117, 347-352	8.7	22
130	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. *Cancer Biology and Therapy*, **2013**, 14, 1098-103	4.6	22
129	Role of MGMT as biomarker in colorectal cancer. *World Journal of Clinical Cases*, **2014**, 2, 835-9	1.6	21
128	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. *Pharmacogenomics Journal*, **2019**, 19, 556-563	3.5	20
127	Caring for Patients With Cancer During the COVID-19 Outbreak in Italy. *JAMA Oncology*, **2020**, 6, 821-822	13.4	20
126	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. *BMC Cancer*, **2017**, 17, 408	4.8	20
125	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. *Journal of Clinical Oncology*, **2018**, 36, 3505-3505	2.2	20
124	Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. *Annals of Surgical Oncology*, **2016**, 23, 4222-4230	3.1	19

123	The landscape of d16HER2 splice variant expression across HER2-positive cancers. *Scientific Reports* , **2019**, 9, 3545	4.9	18
122	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. *Targeted Oncology*, **2016**, 11, 337-43	5	18
121	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. *Medical Oncology*, **2015**, 32, 182	3.7	18
120	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. *Oncologist*, **2020**, 25, 803-809	5.7	17
119	miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. *EMBO Molecular Medicine*, **2018**, 10,	12	17
118	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. *Oncologist*, **2017**, 22, 1463-1469	5.7	17
117	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. *PLoS ONE*, **2014**, 9, e92147	3.7	17
116	Microsatellite instability in Gastric Cancer: Between lights and shadows. *Cancer Treatment Reviews*, **2021**, 95, 102175	14.4	17
115	The Landscape of Actionable Gene Fusions in Colorectal Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	17
114	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. *Critical Reviews in Oncology/Hematology*, **2016**, 98, 24-8	7	16
113	Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. *European Journal of Cancer*, **2017**, 86, 197-206	7.5	16
112	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. *Clinical Colorectal Cancer*, **2020**, 19, 219-225	3.8	16
111	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. *ESMO Open*, **2018**, 3, e000403	6	15
110	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. *Journal of Clinical Oncology*, **2019**, 37, 66-66	2.2	15
109	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. *European Journal of Cancer*, **2021**, 150, 155-167	7.5	15
108	CK7 and consensus molecular subtypes as major prognosticators in BRAF mutated metastatic colorectal cancer. *British Journal of Cancer*, **2019**, 121, 593-599	8.7	14
107	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. *Oncology*, **2019**, 97, 38-43	3.6	14
106	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. *Nature Communications*, **2018**, 9, 2287	17.4	14

105	Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. *International Journal of Molecular Sciences*, **2015**, 16, 8884-95	6.3	13
104	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. *Critical Reviews in Oncology/Hematology*, **2015**, 95, 272-81	7	13
103	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. *Oncologist*, **2020**, 25, e460-e468	5.7	13
102	Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. *Annals of Surgical Oncology*, **2018**, 25, 878-884	3.1	13
101	BRAF in metastatic colorectal cancer: the future starts now. *Pharmacogenomics*, **2015**, 16, 2069-81	2.6	13
100	Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. *Cancers*, **2014**, 6, 1753-68	6.6	13
99	Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. *Translational Oncology*, **2012**, 5, 155-9	4.9	13
98	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. *Cell Death and Differentiation*, **2021**, 28, 2778-2796	12.7	13
97	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. *JAMA Oncology*, **2021**, 7, 1529-1535	13.4	13
96	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. *European Journal of Cancer*, **2015**, 51, 473-481	7.5	12
95	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. *Clinical Colorectal Cancer*, **2020**, 19, 156-164	3.8	12
94	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. *Scientific Reports*, **2019**, 9, 12993	4.9	11
93	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. *Pharmacogenomics Journal*, **2019**, 19, 465-472	3.5	11
92	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. *Critical Reviews in Oncology/Hematology*, **2016**, 100, 99-106	7	11
91	BRAF-mutated metastatic colorectal cancer between past and future. *British Journal of Cancer*, **2015**, 113, 1634-5	8.7	10
90	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. *British Journal of Cancer* , **2018**, 118, 955-965	8.7	10
89	Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. *Oncologist*, **2012**, 17, 1426-8	5.7	10
88	Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer. *Tumori*, **2016**, 102, e15-9	1.7	10

87	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. *International Journal of Cancer*, **2019**, 145, 576-585	7.5	10
86	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. *Clinical Colorectal Cancer*, **2020**, 19, 191-199.e6	3.8	10
85	Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. *Pharmacogenomics*, **2018**, 19, 1047-1068	2.6	9
84	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. *Oncology*, **2018**, 95, 344-352	3.6	9
83	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. *Clinical Colorectal Cancer*, **2017**, 16, e191-e198	3.8	9
82	Prognostic factors after R0 resection of colorectal cancer liver metastases: A systematic review and pooled-analysis. *Reviews on Recent Clinical Trials*, **2016**, 11, 56-62	1.2	9
81	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. *Cancer Research and Treatment*, **2017**, 49, 834-845	5.2	9
80	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2020**, 138, 1-10	7.5	9
79	How the lab is changing our view of colorectal cancer. *Tumori*, **2016**, 102, 541-547	1.7	9
78	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. *Future Oncology*, **2017**, 13, 2265-2275	3.6	8
77	Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. *ESMO Open*, **2019**, 4, e000489	6	8
76	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. *BMC Cancer*, **2019**, 19, 283	4.8	8
75	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. *Oncology*, **2017**, 93, 279-286	3.6	8
74	TP53 mutations in advanced colorectal cancer: the dark side of the moon. *Oncology*, **2014**, 86, 289-94	3.6	8
73	Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2014**, 37, 545-9	2.7	8
72	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2020**, 26, 1017-1024	12.9	8
71	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. *European Journal of Cancer*, **2021**, 146, 74-83	7.5	8
70	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. *Clinical Colorectal Cancer*, **2019**, 18, e179-e190	3.8	7

69	Role of BAX for outcome prediction in gastrointestinal malignancies. *Medical Oncology*, **2013**, 30, 610	3.7	7
68	Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. *Targeted Oncology*, **2011**, 6, 181-6	5	7
67	Acute Immune-Mediated Thrombocytopenia Due to Oxaliplatin Administration: A Case Report. *Tumori*, **2010**, 96, 154-156	1.7	7
66	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. *Cancer Treatment Reviews*, **2020**, 82, 101935	14.4	7
65	Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. *Cells*, **2020**, 9,	7.9	7
64	TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. *Cancers*, **2021**, 13,	6.6	7
63	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. *International Journal of Cancer*, **2020**, 147, 2303-2315	7.5	7
62	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. *Pharmacogenomics Journal*, **2017**,	3.5	6
61	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. *European Journal of Cancer*, **2020**, 135, 230-239	7.5	6
60	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. *BMC Cancer*, **2018**, 18, 98	4.8	6
59	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality.. *JCO Precision Oncology*, **2019**, 3, 1-14	3.6	6
58	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. *ESMO Open*, **2017**, 2, e000241	6	6
57	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. *European Journal of Cancer*, **2019**, 107, 164-174	7.5	6
56	Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. *Clinical Cancer Research*, **2021**, 27, 3126-3140	12.9	6
55	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. *European Journal of Cancer*, **2021**, 146, 145-154	7.5	6
54	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. *Clinical Colorectal Cancer*, **2019**, 18, 116-124	3.8	5
53	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. *European Journal of Cancer*, **2020**, 135, 78-88	7.5	5
52	A systematic review of salvage therapies in refractory metastatic colorectal cancer. *International Journal of Colorectal Disease*, **2020**, 35, 783-794	3	5

51	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors **2021**, 9,		5
50	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. *Clinical Colorectal Cancer*, **2019**, 18, 34-43.e6	3.8	5
49	The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. *European Journal of Surgical Oncology*, **2021**, 47, 4-10	3.6	5
48	Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. *Annals of Surgical Oncology*, **2021**, 28, 3332-3342	3.1	5
47	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2021**, 144, 31-40	7.5	5
46	Glomerular filtration rate: A prognostic marker in atrial fibrillation-A subanalysis of the AntiThrombotic Agents Atrial Fibrillation. *Clinical Cardiology*, **2018**, 41, 1570-1577	3.3	5
45	Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. *Personalized Medicine*, **2014**, 11, 259-262	2.2	4
44	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. *Cancers*, **2021**, 13,	6.6	4
43	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. *Oncologist*, **2021**, 26, 302-309	5.7	4
42	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. *Journal of the National Cancer Institute*, **2021**,	9.7	4
41	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. *Journal of Clinical Oncology*, **2022**, JCO2102583	2.2	4
40	Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients. *Expert Review of Molecular Diagnostics*, **2018**, 18, 259-277	3.8	3
39	LightSNiP assay is a good strategy for pharmacogenetics test. *Frontiers in Pharmacology*, **2015**, 6, 114	5.6	3
38	Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab. *Medical Oncology*, **2012**, 29, 2838-41	3.7	3
37	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. *Oncology Reviews*, **2009**, 3, 79-87	4.3	3
36	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.. *European Journal of Cancer*, **2021**, 161, 90-98	7.5	3
35	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. *JCO Precision Oncology*, **2020**, 4,	3.6	3
34	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. *European Journal of Cancer*, **2020**, 139, 81-89	7.5	3

33	EGFR Amplification in Metastatic Colorectal Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 1561-1569	9.7	3
32	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. *Supportive Care in Cancer*, **2021**, 29, 3971-3980	3.9	3
31	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 2505-2514	12.9	3
30	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). *ESMO Open*, **2018**, 3, e000389	6	3
29	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. *Journal of Molecular Diagnostics*, **2020**, 22, 685-698	5.1	2
28	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. *Clinical and Translational Oncology*, **2013**, 15, 582-6	3.6	2
27	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. **2022**, 10,		2
26	Skin Toxicity as Predictor of Survival in Refractory Patients with Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. *Cancers*, **2021**, 13,	6.6	2
25	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. *Tumori*, **2021**, 107, 353-359	1.7	2
24	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. *Tumori*, **2021**, 107, 150-159	1.7	2
23	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors **2021**, 9,		2
22	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.. *Journal of Clinical Oncology*, **2022**, JCO2102453	2.2	2
21	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.. *JCO Precision Oncology*, **2022**, 6, e2200015	3.6	2
20	In reply. *Oncologist*, **2015**, 20, e5	5.7	1
19	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. *Clinical Interventions in Aging*, **2015**, 10, 127-33	4	1
18	FOLFIRI with cetuximab or bevacizumab: FIRE-3. *Lancet Oncology, The*, **2014**, 15, e581	21.7	1
17	Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. *Drugs and Aging*, **2011**, 28, 83-91	4.7	1
16	An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review. *Tumori*, **2010**, 96, 1031-1034	1.7	1

15	Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. *Annals of Oncology*, **2012**, 23, 2771-2772	10.3	1
14	New perspectives in advanced genitourinary malignancies. *Tumori*, **2012**, 98, 267-9	1.7	1
13	Personalized therapeutic strategies in HER2-driven gastric cancer. *Gastric Cancer*, **2021**, 24, 897-912	7.6	1
12	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. *European Journal of Cancer*, **2021**, 153, 16-26	7.5	1
11	MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Response. *Clinical Cancer Research*, **2020**, 26, 3495	12.9	0
10	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. *Oncologist*, **2022**, 27, e29-e36	5.7	0
9	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. *ESMO Open*, **2019**, 4, e000496	6	0
8	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma.. *JCO Precision Oncology*, **2022**, 6, e2100472	3.6	0
7	BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications.. *Critical Reviews in Oncology/Hematology*, **2022**, 103647	7	0
6	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.. *European Journal of Cancer*, **2022**, 167, 23-31	7.5	0
5	Negative Ultraselection of Patients With / Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.. *JCO Precision Oncology*, **2022**, 6, e2200037	3.6	0
4	Reply to the letter to the editor "new life for retrospective study in the precision oncology era" by Orlandi et al. *Annals of Oncology*, **2015**, 26, 2353	10.3	
3	Molecular Determinants of Gastrointestinal Cancers. *Advances in Oncology*, **2021**, 1, 311-325		
2	Atypical Mutations in Metastatic Colorectal Cancer.. *JCO Precision Oncology*, **2019**, 3, 1-11	3.6	
1	Management of advanced genitourinary tumors. *Tumori*, **2012**, 98, 264-6	1.7	